深圳欣博盛生物科技有限公司

IL-33 (oxidation resistant) (human) (monomer):Fc (silent) InVivoKine™

InVivoKine™; IL-33 (human) (C208S/C232S Mutant):Fc Knobs-into-Holes (human) (rec.); Interleukin-33 (human) (C208S/C232S Mutant); IL-1F11; NF-HEV

Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3) / ERK2 (MAPK1), p38 (MAPK14) and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis. IL-33 facilitates Treg expansion in vitro and in vivo. Recently, IL-33 has been involved in adipocyte differentiation. The biological activity of IL-33 at its receptor ST2 is rapidly terminated in the extracellular environment by its oxidation (formation of two disulfide bridges), resulting in an extensive conformational change that disrupts the ST2 binding site. Mutations at amino acids C208S/C232S protect IL-33 from oxidation and increase its activity. The IL-33 (oxidation resistant) (human) (monomer):Fc (silent) InVivoKine™ is produced by using two different vectors, one encoding for the IL-33 (human) (oxidation resistant):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 55kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization and for secretion of the final protein IL-33 (oxidation resistant) (human) (monomer):Fc (silent) InVivoKine™. The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.

HEK 293 cells. Produced using animal component-free medium.

Binds to human and mouse ST2. The Fc contains the mutations LALA-PG that abolish the interaction between the Fc and FcgammaRs and therefore Fc undesirable effects.

After reconstitution: 1mg/ml

+4°C

BI

~55kDa and 28 kDa (SDS-PAGE)

solid

Lyophilized. Contains PBS

瑞士

>95% (SDS-PAGE)

<0.01EU/µg purified protein (LAL test).